AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02472912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMO-2
Description: Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
Study NCT02472912 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Humira
Description: Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
Study NCT02472912 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-Humira
Description: Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
Study NCT03446898 — intervention group
Intervention type: OTHER
Intervention: Chronic hypoxic environment
Description: Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
Study NCT02859974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory retraining for PVFMD
Description: Patients serve as their own controls. During a three week baseline, participants will complete the Dyspnea Index (DI), and have their heart rate, Resp. minute volume and ETCO2 on days 1 and 21 (or on the day treatment commences). Participants will complete a daily log reporting their daily symptoms. This will serve as the baseline prephase.~Post 1 phase will include five individual therapy sessions teaching the respiratory retraining techniques over an estimated three week period.~Post2 phase will comprise of a six week home practice phase. There will be four measuring points per participant: pre1/pre2 measurements on day 1 and 21 (or on the day therapy begins), post1 upon completing five therapy sessions and post 2 upon completion of the home practice phase.
Study NCT00339040 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)
Description: QHPV at week 0, 8, 24 and 96.
Study NCT00339040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo/QHPV
Description: Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
Study NCT01269684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
Study NCT00940550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin
Description: 2 mg tablet, once.
Study NCT00940550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temazepam
Description: 20 mg capsule, once
Study NCT00940550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: 10 mg capsule, once
Study NCT00940550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match melatonin, zolpidem and temazepam
Description: Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
Study NCT03130829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligo Fucoidan
Description: Oral, twice daily
Study NCT03130829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, twice daily
Study NCT00712517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol anesthesia 3-5mg/kg
Study NCT00712517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: sevoflurane anesthesia
Study NCT04474639 — intervention group
Intervention type: DEVICE
Intervention: echocardiographic examination
Description: conducting an echocardiographic study according to a standard protocol with the determination of diastolic dysfunction of the left ventricle
Study NCT04221633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Early Engagement (E3) webinar
Description: Webinar-based training to provide information regarding evidence-based engagement strategies (e.g., motivational interviewing, McKay's engagement model), trauma, mental health screening, and identifying evidence-based mental health treatments for children.
Study NCT04221633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation for E3 training
Description: 10 consultation calls with experts in engagement, child trauma, and mental health screening to support the webinar training
Study NCT03261895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Integrative health and wellness programme
Description: Participants in the intervention group will go through a eight-session structured education programme. The education programme was designed by incorporating the evidences of diabetes care from the western medicine and the philosophy of traditional Chinese medicine.
Study NCT02538120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microvascular assessment
Description: Microvascular assessment
Study NCT00819429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
Study NCT00819429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: 1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
Study NCT00904995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.
Study NCT00660777 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Deep breathing, bilateral alternate chewing, nasal lavage
Description: Deep breathing, bilateral alternate chewing, nasal lavage
Study NCT00819429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment (or TAU in Child Guidance Clinic)
Description: Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
Study NCT00819429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment (or TAU in Child Guidance Clinic)
Description: Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
Study NCT00660777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal exercises
Description: Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
Study NCT02764645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioGard Cannula
Description: CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration.
Study NCT02764645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22Fr curved Cannula
Description: arterial cannula for use in cardiac surgery
Study NCT03046810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wellness toileting system
Description: This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
Study NCT00477308 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: salvage therapy
Study NCT03791892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder mobilization Group
Description: Suprascapular nerve block administered every week to both groups. Joint mobilization (3 sets / 40 seconds hold / 30 seconds interval) Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Strengthening exercises ( 3 sets / 15 reps)
Study NCT03791892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment Group
Description: Suprascapular nerve block administered every week to both groups. Daily Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Daily Strengthening exercises ( 3 sets / 15 reps)
Study NCT03544515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Description: Application of Er,Cr:YSGG in peri-implantitis cases as a coadjutant has shown reduction in the pocket depths and bleeding on probing
Study NCT03544515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling
Description: Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)
Study NCT03544515 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Scaling
Description: Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)
Study NCT03544515 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Er,Cr:YSGG
Description: Er,Cr:YSGG laser (inactive form - sham procedure) applied to the surface of the implant
Study NCT03175172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: Administered by IV infusion over approximately 1 hour.
Study NCT03175172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by IV infusion over approximately 30 minutes.
Study NCT03840421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
Study NCT03840421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin and fluorouracil
Description: Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
Study NCT03840421 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor
Study NCT03840421 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor
Study NCT03840421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
Study NCT02990650 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Task Training with therapist guarding support
Description: Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The therapist will provide guarding support
Study NCT02990650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance task training with robotic guarding support
Description: Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot
Study NCT02990650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challneged balance task training with robotic guarding support
Description: Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot
Study NCT02818517 — intervention group
Intervention type: OTHER
Intervention: ACE inhibitors
Description: Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
Study NCT02818517 — intervention group
Intervention type: OTHER
Intervention: beta blockers
Description: Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
Study NCT04097652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMC119-06
Description: Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
Study NCT03840421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
Study NCT00737035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Healthcare Communication Application
Description: The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an Ask an Expert system staffed by researchers; and (6) personal stories of others dealing with IPH.
Study NCT00737035 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Web sites
Description: Only publicly available Web sites on parenting, child development, and trauma will be used.
Study NCT00507338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: early PCI for NSTEMI; primary PCI for STEMI
Study NCT00507338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: early PCI for NSTEMI; primary PCI for STEMI
Study NCT03815136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Gum
Description: Patients of CG group chewed one piece of sugarless gum for approximately 15 min every 30 min at the first hour of the examination.
Study NCT00706381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV and/or oral placebo
Study NCT02664363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRvIII CAR T cells
Description: The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
Study NCT01077466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: 300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
Study NCT02251873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV + RTV (low dose)
Study NCT02251873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV + RTV (high dose)
Study NCT02251873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ddl
Study NCT00115297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
Study NCT00115297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who were 2 to 3 years old received placebo montelukast tablets and participants who were 12 months to 2 years old received placebo montelukast granules.
Study NCT02508753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-101/tazobactam
Description: 1000/500 mg single IV dose administered over 60 minutes
Study NCT02508753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-101/tazobactam
Description: 3000/1500 mg single IV dose administered over 60 minutes
Study NCT02508753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg tablet
Study NCT02508753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
Study NCT01915693 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
Study NCT01172821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo that represents BI drug
Study NCT01172821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo that represents comparator
Study NCT01172821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo that represents comparator
Study NCT01172821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat® low dose
Description: IMP
Study NCT01172821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo that represents BI drug
Study NCT01172821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat® high dose
Description: IMP
Study NCT01172821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mcg salmeterol HFA MDI
Description: Active comparator
Study NCT01215513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study NCT03714360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: patients with ASA(American Society of Anesthesiologists grades) 1 to 2, scheduled to undergo lumbar decompressive surgery at Middelfart Hospital. Patients were randomized, in blocks of 10, to two groups: TXA or placebo. Anticoagulation therapy was discontinued 2-7 days preoperatively. Prior to the incision, patients received either a bolus of TXA (10mg/kg), or an equivalent volume of saline solution (placebo).
Study NCT03714360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0,9%
Description: Sodium Chloride 0,9%
Study NCT00249691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate + Cognitive Behavioral Therapy
Description: Topiramate up to 300 mg per day
Study NCT00249691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy
Description: Placebo twice a day
Study NCT04072016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beacon Aqueous Microshunt
Description: The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.
Study NCT00644449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT00644449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR (Zithromax; compound: CP-62,993)
Description: azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
Study NCT00644449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: 500 mg (two 250 mg capsules) by mouth once daily for 7 days
Study NCT03145831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somavaratan
Description: All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
Study NCT01708629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered SC
Study NCT01708629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered SC
Study NCT01708629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg brodalumab
Description: 140 mg brodalumab administered SC
Study NCT01708629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: 45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.